I think this is a real great tech story. In this category there are limited players, Biovac the Canadian company I think its called now in stage 3 trials got $500m payment and another $500m in two stages payments based on mile stones. Cavatak is a smaller virus so it gets in more places and having better results. I think large farmers will be talking to VLA. The large international Bio funds who are buying on market, got set at 26c last capital raising this is very smart money they do very good DD.
The share price only trades on small volumes and when you look at it the market looks like it has electronic trading in it setting the price and sucking out stock. I think they have a very long tail of unmarketable size holders which doesn't help things.
One interesting development is now that many cancer drug developers are now giving patients a flue virus to turn on the immune system so there drug works better, my not use Cavatak to front attack. This give this drug so much upside as it will let drug companies sell two drugs and keep existing drugs relevant and good news for patients.
VLA Price at posting:
28.5¢ Sentiment: Buy Disclosure: Held
